Slide 1 New Opportunities to Enhance the Clinical Outcomes of Patients With Follicular Lymphoma Bruce D. Cheson, MD Head of Hematology Deputy Chief, Hematology/Oncology Georgetown…

Slide 1 Leukocyte Disorders Part 2 Lymphomas and Other Disorders Walter C. Bell, MD Slide 2 Normal Lymph Node Slide 3 Acute Nonspecific Lymphadenitis Lymph node enlargement…

Slide 1 Stephanie A. Gregory, MD, FACP The Elodia Kehm Chair of Hematology Professor of Medicine Rush University Medical Center/Rush University Chicago, Illinois, USA Treatment…

Slide 1 Assessing Response in Malignant Lymphoma Lieselot Brepoels Sigrid Stroobants UZ Gasthuisberg, Leuven, Belgium Slide 2 Introduction  Wide range of pathobiologically…

Slide 1 The State of Whole Genome, Exome and Transcriptome Sequencing September-2011 (WGS/WES/RNAseq) Slide 2 Information Sources  dbGAP dbGAP  EGA EGA  GEO GEO…

New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL…

Grand Rounds Grand Rounds Conference Eric Downing MD University of Louisville Department of Ophthalmology and Visual Sciences Subjective CC/HPI: 77M referred by a local oncologist…

CARCINOGENESIS Carcinogenesis Main changes in the cell physiology that lead to formation of the malignant phenotype: A- Self-sufficiency in growth signals B- Insensitivity…

Novel agents for indolent lymphoma and MCL Novel Agents for Indolent Lymphoma and Mantle Cell Lymphoma Stephen Ansell, MD, PhD Mayo Clinic 1 Tiacci et al, Nature Reviews…

Bendamustine-Rituximab (B-R) vs CHOP-R Bendamustine-Rituximab (N=139) - Bendamustine 90 mg/m2 day 1+2 Rituximab 375 mg/m2 day 1 CHOP-Rituximab (N=140) - Cyclophosphamide…